Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
iX Biopharma Ltd. ( (SG:42C) ) has issued an update.
iX Biopharma is consolidating its Australian and Hong Kong consumer assets, a portfolio of about 40 WaferiX-based formulations, and a planned direct-to-consumer telehealth platform into a new wholly owned holding company, Ligo Pharma Pte. Ltd. Ligo will hold the commercial licence to iX’s sublingual delivery technology for consumer applications and serve as the company’s primary vehicle for its U.S. market push, while Wafermine, related regulatory assets, and U.S. Department of Defence obligations remain with iX.
iX’s board says the reorganisation is designed to accelerate entry into the fast-growing U.S. longevity and lifestyle health market via the 503A/503B compounding framework, position the group for peptide-based opportunities, and enable U.S.-based manufacturing, all while creating a standalone consumer business that could support future spin-off or listing options. In parallel, iX is in advanced talks on a joint venture that would fold Nevada-based Orion Specialty Labs into the Ligo structure, with GLD Partners becoming a co-shareholder, potentially deepening its U.S. footprint and funding base, though terms are still under negotiation and investors are urged to trade with caution.
The most recent analyst rating on (SG:42C) stock is a Buy with a S$1.00 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock Forecast page.
More about iX Biopharma Ltd.
iX Biopharma Ltd. is a Singapore-incorporated pharmaceutical group focused on its patented WaferiX sublingual drug delivery platform, with operations spanning Australia and Hong Kong. The company targets both regulated pharmaceutical products, such as its Wafermine pain therapy, and emerging consumer health segments, including longevity and lifestyle markets in the U.S., leveraging telehealth and compounding channels.
Average Trading Volume: 19,200,743
Technical Sentiment Signal: Buy
Current Market Cap: S$430.9M
Learn more about 42C stock on TipRanks’ Stock Analysis page.